NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Thanks for sharing. I’m a little taken back GZ stating

"Whether it’s a full or conditional approval remains to be determined, but either way it will enable us to launch DCVax-L in the U.K."

I didn’t think conditional approval would be in the cards for GBM/rGBM but would be in the cards for a grade 3 or less glioma. The way he said it puts conditional approval on the table for GBM/rGBM. As he said either way DCVax-L would be a marketed drug but w conditional approval there would be more rigorous annual renewals to ensure compliance. And w either full or conditional approval, they would no doubt be running additional trials to support/expand initial approval. Still GZs statement is a little bit of an eye opener.